Skip to content
Triangle logo TriangleGet started
← Study library

NCT00874419 · CITED IN SOURCE DOCUMENTS

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2014-09-25

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as erlotinib have proved effective in second or third line therapy for advanced non-small cell lung cancer(NSCLC).It is well tolerated without the side effects usually associated with chemotherapy. The mutations in EGFR exons 19 or 21 have been reported to be associated with efficacy of EGFR TKIs.Based on the encouraging preliminary results from the Spanish lung cancer group' prospective study reported that the efficacy of Tarceva as first line treatment for metastatic NSCLC patients with EGFR mutation would delay disease progression,prolong overall survival and be well tolerated, medium Progression-free survival(PFS) was around 12 months and OS reach 24 months，our study is designed to compare PFS between the patients with mutant EGFR treated by gemcitabine/carboplatin and those by erlotinib in the first-line setting. We assumed 11 months of PFS on Tarceva arm versus 6 months on chemotherapy arm with a=0.025(alpha-spend for an interim analysis), 80% power and 12 months enrolment period, 12 months FU duration to calculate the sample size. The sample size is 69 pairs. Considering about 10% drop-out rate, the final sample size is 152 patients.So, chemo-naive staged IIIb/IV patients with EGFR mutations in exon 19 or 21 will be enrolled into this open-label, randomized,multicenter phase III study.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: 1. Stage IIIB (cytological confirmed with malignant pleural effusion or pericardial effusion) or histopathological or cytological confirmed stage IV NSCLC or relapsed after complete resection . 2. EGFR exon19 deletions or exon 21 L858R mutation by the DNA direct PCR sequencing using fresh tumor sample or paraffin embed tumor sample. 3. Measurable lesions as defined by RECIST criteria . 4. Palliative radiotherapy allowed if it was finished 3 weeks after the first drug administration, but the target lesions should not be included in the radiotherapy field. 5. Patients with operation are allowed if the operation is 4 weeks before the first drug administration 6. Men or women of at least 18 years of age. 7. ECOG Performance status of 0 to 2. 8. Estimated life expectancy of at least 12 weeks. 9. Patient compliance and geographic proximity that allow adequate follow-up. 10. Adequate organ function tested 7 days before the first drug administration: hemoglobin ≥9 g/dL,absolute neutrophil count (ANC) ≥1.5\*109/L, platelets ≥100 \*109/L,bilirubin ≤1.5ULN, alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 upper limited number(ULN) (AP, AST, ALT ≤5ULN is acceptable if liver has tumor involvement).INR≤1.5, APTT in the normal range( 1.2DLN-1.2ULN),creatinine ≤1.5ULN. 11. Informed consent from the patient. Exclusion Criteria: 1. Have received systemic anti-cancer therapy, including Cytotoxic drugs, targeted therapy, experimental treatment, adjuvant or neo-adjuvant therapy(except the disease relapse 6 months after the final drug) 2. Wild type EGFR. 3. Uncontrolled pericardial or pleural effusions prior to study entry. 4. History of cardiovascular disease: Congestive Heart Failure \> grade II in NYHA. Unstable angina patients (have angina symptoms in rest) or a new occurrence of angina (began in the last 3 months) or myocardial infarction happens in the last 6 months 5. Brain metastasis (controlled brain metastasis and steroid free need is excluded). 6. HIV infection 7. Active infection, \>grade 2 in Common Terminology Criteria for Adverse Events(CTCAE) version 3. 8. A history of operation or serious traumatic 3 weeks before the first drug administration 9. Patient with other malignant tumor except NSCLC 5 years previous to study entry. Excluding cervical carcinoma in situ, cured basal cell carcinoma, bladder epithelial tumor \[including Ta and Tis\] 10. Mixed with small cell lung cancer 11. Unable to swallow drugs. 12. Malabsorption 13. Pregnant or child breast feeding women 14. Childbearing patients will not use a reliable method of contraception before the study entry, during process of the study and within 30 days after discontinuation of the study. Reliable contraceptive methods will be determined by principal investigator or a designated officer.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Arm 1 receive erlotinib 150 mg oral, once a day until progression or unacceptable toxicity
    intervention Names
    1. Drug: erlotinib
    label
    erlotinib
    type
    EXPERIMENTAL
  2. description
    gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
    intervention Names
    1. Drug: gemcitabine/carboplatin
    label
    gemcitabine/carboplatin
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. erlotinib
    description
    erlotinib 150 mg oral, once a day
    name
    erlotinib
    other Names
    1. Tarceva
    type
    DRUG
  2. arm Group Labels
    1. gemcitabine/carboplatin
    description
    gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
    name
    gemcitabine/carboplatin
    other Names
    1. Gemzar
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
165
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Progression free survival
    time Frame
    12 months
secondary Outcomes
  1. measure
    OS
    time Frame
    24 months
  2. measure
    ORR
    time Frame
    24 months
  3. measure
    Time to Progression
    time Frame
    24 months
  4. measure
    lung cancer symptoms and health-related quality of life (HRQoL)
    time Frame
    24 months
  5. measure
    explore the biological markers (tumor tissue)
    time Frame
    24 months
Full study description
brief Summary
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as erlotinib have proved effective in second or third line therapy for advanced non-small cell lung cancer(NSCLC).It is well tolerated without the side effects usually associated with chemotherapy. The mutations in EGFR exons 19 or 21 have been reported to be associated with efficacy of EGFR TKIs.Based on the encouraging preliminary results from the Spanish lung cancer group' prospective study reported that the efficacy of Tarceva as first line treatment for metastatic NSCLC patients with EGFR mutation would delay disease progression,prolong overall survival and be well tolerated, medium Progression-free survival(PFS) was around 12 months and OS reach 24 months，our study is designed to compare PFS between the patients with mutant EGFR treated by gemcitabine/carboplatin and those by erlotinib in the first-line setting. We assumed 11 months of PFS on Tarceva arm versus 6 months on chemotherapy arm with a=0.025(alpha-spend for an interim analysis), 80% power and 12 months enrolment period, 12 months FU duration to calculate the sample size. The sample size is 69 pairs. Considering about 10% drop-out rate, the final sample size is 152 patients.So, chemo-naive staged IIIb/IV patients with EGFR mutations in exon 19 or 21 will be enrolled into this open-label, randomized,multicenter phase III study.
detailed Description
Primary Outcome Measures: Progression-free survival(PFS) Secondary Outcome Measures: Overall response rate(ORR), overall survival(OS), quality of life(QOL),etc. Estimated Enrollment: 160 Study Start Date: August 2008 Estimated Study Completion Date: August 2010 The patients will be randomized into the following two arms: Arm A: erlotinib 150mg once per day up to disease progression or intolerable toxicity. Arm B: Gemcitabine (1000mg/m2, IV,d1 and d8) plus Carboplatin (AUC=5, IV d1) repeated every 3 weeks up to 4 cycles.
Source references
references
  1. citation
    Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 Sep;26(9):1877-1883. doi: 10.1093/annonc/mdv276. Epub 2015 Jul 3.
    pmid
    26141208
    type
    DERIVED
  2. citation
    Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
    pmid
    21783417
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-abfde4f8056365e95faf
      requested nct id
      NCT00874419
      primary nct id
      NCT00874419
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
      payload sha256
      3899a2fc8bb5976d3a9cb83afa72b2b3514dc2ef0f2fa5c0e5d543b374ee4a9a
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-abfde4f8056365e95faf
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00874419
      occurrences
      1. context exact
        4" tabindex="-1">Evidence (erlotinib):</p> <div class="pdq-content-list"><ol id="_484916"><li>An open-label phase III trial (<a href="/clinicaltrials/NCT00874419">NCT00874419</a>) from China included 165 patients older than 18 years with histologically confirmed stage IIIB/IV NSCLC and confirmed activating <em class="ge
        end
        499468
        exact text
        NCT00874419
        start
        499457
      2. context exact
        -1">Evidence (erlotinib):</p> <div class="pdq-content-list"><ol id="_484916"><li>An open-label phase III trial (<a href="/clinicaltrials/NCT00874419">NCT00874419</a>) from China included 165 patients older than 18 years with histologically confirmed stage IIIB/IV NSCLC and confirmed activating <em class="gene-name">EGFR
        end
        499481
        exact text
        NCT00874419
        start
        499470
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/11a3437f29dc92742e.html
      source file sha256
      6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:59.782436+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      96af5062fe49c6481bdc1ef6946e69939f30c810b02e368845c837ccf6c0977c
      source title
      Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 15, 2025
        datetime
        2025-05-15T12:00:00Z
        display
        May 15, 2025

    Preserved source evidence · Not medical advice